Muc2 Mucin and Nonmucin Microbiota Confer Distinct Innate Host Defense in Disease Susceptibility and Colonic Injury

Aralia Leon-Coria,1,* Manish Kumar,1,* Matthew Workentine,2 France Moreau,1 Michael Surette,1,3 and Kris Chadee1

1Department of Microbiology, Immunology and Infectious Diseases, University of Calgary Health Sciences Centre, Calgary, Alberta, Canada; 2Department of Veterinary Medicine, University of Calgary, Calgary, Alberta, Canada; and 3Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada

SUMMARY

This study interrogates the impact of alterations in the microbial composition in animals with and without Muc2 mucus in colonic epithelial barrier dysfunction and inflammation. The absence of a protective mucus barrier alters microbiota to promote inflammation and intestinal permeability.

BACKGROUND & AIMS: Alterations in intestinal MUC2 mucin and microbial diversity are closely linked with important intestinal pathologies; however, their impact on each other and on intestinal pathogenesis has been vaguely characterized. Therefore, it was of interest in this study to delineate distinct and cooperative function of commensal microbiota and the Muc2 mucus barrier in maintaining intestinal epithelial barrier function.

METHODS: Muc2 mucin deficient (Muc2−/−) and sufficient (Muc2+/+) littermates were used as a model for assessing the role of Muc2. To quantify the role of the microbiota in disease pathogenesis, Muc2−/− and Muc2+/− littermates were treated with a cocktail of antibiotics that reduced indigenous bacteria, and then fecal transplanted with littermate stool and susceptibility to dextran sulphate sodium (DSS) quantified.

RESULTS: Although, Muc2+/+ and Muc2−/− littermates share similar phyla distribution as evidenced by 16S sequencing they maintain their distinctive gastrointestinal phenotypes. Basally, Muc2−/− showed low-grade colonic inflammation with high populations of inflammatory and tolerogenic immune cells that became comparable to Muc2+/+ littermates following antibiotic treatment. Antibiotics treatment rendered Muc2+/+ but not Muc2−/− littermates highly susceptibility to DSS-induced colitis that was ILC3 dependent. Muc2−/− microbiota was colitogenic to Muc2+/+ as it worsened DSS-induced colitis. Microbiota dependent inflammation was confirmed by bone-marrow chimera studies, as Muc2−/− receiving Muc2+/+ bone marrow showed no difference in their susceptibility toward DSS induced colitis. Muc2−/− microbiota exhibited presence of characteristic OTUs of specific bacterial populations that were transferrable to Muc2+/+ littermates.

CONCLUSIONS: These results highlight a distinct role for Muc2 mucin in maintenance of healthy microbiota critical in shaping innate host defenses to promote intestinal homeostasis. (Cell Mol Gastroenterol Hepatol 2021;11:77–98; https://doi.org/10.1016/j.jcmgh.2020.07.003)

Keywords: Muc2; Microbiota; Colitis; Dysbiosis; Mucus.
A diverse population of microorganisms, collectively called the “gut microbiota,” have adapted to live symbiotically in/on the intestinal mucosal surface and play a critical role in host nutrition and immune modulation. Their effects are largely dependent on complex interactions with host immune cells, and any imbalance could result in the development of disease. It has been estimated that approximately 100 billion bacteria of around 500–1000 species, encompassing 7–9 phyla, are present in the human gut. This huge diversity of gut microbiota largely dictates the outcome of host-microbiota interactions, as revealed by 16S rRNA sequencing and metagenomic analysis of healthy and inflammatory bowel disease (IBD) patients. Although genetic and environmental factors largely determine gut microbial diversity, 90% of gut bacteria belong to the phyla Firmicutes and Bacteroidetes in healthy individuals. However, some IBD patients have reduced biodiversity (alpha diversity) with a concomitant rise in pathobionts resulting in impaired activation of the host immune system. Even though a reduction in Firmicutes and rise in Proteobacteria is consistently seen in IBD patients, there is no direct causal association between specific pathobionts and the development of IBD.

The intestinal mucus layer is formed of polymeric sheets of densely glycosylated MUC2 mucin. Depletion of the mucus layer is one of the most common characteristics in IBD patients, allowing gut microbial components to come in close contact with host cells and to elicit unregulated inflammation. A higher number of adherent-invasive Escherichia coli isolates have been observed in rectal biopsies from IBD patients. However, it is uncertain whether depletion of the mucus layer is a risk factor or a result of colonic inflammation in IBD patients. Findings by us and others have reaffirmed the importance of the mucus layer in maintaining homeostasis between gut microbiota and the host immune system. Recent studies have suggested specific groups of bacteria and their metabolites may have potent immune-modulatory effects on the host immune system. Thus, any alteration in microbial dynamics can predispose the host toward aggravated disease. Even though there is ample evidence to verify the close association of microbiota and the mucus layer in IBD pathogenesis, the exact role of each other on events responsible for the initiation and course of IBD is not clear. We hypothesize that these 2 factors, separately or together, can aggravate colonic inflammation to predispose the host toward IBD. Here we used Muc2+/+ and Muc2−/− littermates to highlight the impact of the mucus layer on gut microbial dynamics and their collective influence in maintaining homeostasis between gut microbiota and host immune system.

Results

Muc2−/− Littermates Exhibit Differential Gut Bacterial Composition That Drives Constitutive Colonic Inflammation

To normalize microbiota in both genotypes, littermates were generated using wild-type (WT) and in-house Muc2−/− animals. Characterization of their microbial compositions by 16s rRNA sequencing showed that Muc2+/+ and Muc2−/− littermates had similar bacterial distribution, with no differences at the phyla level (Figure 1A, lanes a and c). Both genotypes included the phyla Firmicutes, Bacteroidetes, Tenericutes, Proteobacteria, and Actinobacteria in similar proportions. Furthermore, alpha diversity analysis showed similar species richness (Figure 1B); however, beta diversity analysis revealed distinct species diversity among the littermates (Figure 1C).

Muc2−/− mice consistently develop mild colitis that culminated in rectal prolapse around 5 months of age and are highly susceptible toward chemical, bacterial, and parasite-induced colitis. Thus, to investigate the role of microbiota in disease pathogenesis, Muc2+/+ and Muc2−/− littermates were treated with a broad-spectrum antibiotic cocktail, and colonic proinflammatory cytokines transcript levels were analyzed. After antibiotic treatment, Muc2+/+ and Muc2−/− littermates showed a shift in bacterial population and diversity, characterized by a decrease in Firmicutes, an increase in Proteobacteria phyla (Figure 1A, lanes b and d). Under basal conditions, Muc2−/− expressed significantly higher levels of Tnf-α and Il-1β transcripts that were attenuated following antibiotics treatment (Figure 1D). To quantify whether high basal levels of proinflammatory cytokines were driving alterations in epithelial barrier function, intestinal permeability was assessed using fluorescein isothiocyanate (FITC) dextran. As predicted, basally Muc2−/− showed increased intestinal permeability that was attenuated following antibiotics treatment (Figure 1E). Based on these findings and knowing that proinflammatory cytokines can alter tight junction (TJ) permeability, we measured TJ expression in untreated and antibiotic-treated mice. Muc2−/− showed decreased Occludin and Claudin 2 basal expressions that were significantly increased (restored) to basal Muc2+/+ levels following antibiotic treatment (Figure 1F). These results suggest that Muc2 mucin deficiency altered gut microbial composition that promoted colonic proinflammatory responses.

To assess if colonic bacteria were directly involved in eliciting colonic proinflammatory responses and alterations in TJ proteins, we visualized bacteria using fluorescent in situ hybridization. In Muc2+/+, the intact mucus layer physically separating epithelial cells and colonic microbiota is evident, whereas in Muc2−/− littermates, bacteria were in...
Comparison of colonic lamina propria CD3+ lymphocytes from Alpha diversity showed equivalent species richness between similar, with a predominance of Bacteroidetes and Firmicutes. Antibiotics disrupted bacterial population (lanes b and d). (diversity between the 2 untreated genotypes was evident. Colonic tissues samples from were selected using 7-AAD. Live CD19+ B cells and CD3+ T cells were gated through FSC-A vs SSC-A and further interrogated by the ratios of height and width in forward and side scatter to select only single cells population. Thereafter, only live cells were selected using 7-AAD. Live CD19+ B cells and CD3+ T cells were selected for further analysis, n = 3–4, p = 4–6, *p < .05, **p < .01. Abx antibiotics; NMDS, nonmetric scaling.

Figure 1. (See previous page). Muc2+/- microbiota drives colonic inflammation and increases gut permeability that is normalized following antibiotic treatment. (A) The 16s rRNA sequencing of Muc2+/+ and Muc2+/- littersmates stool microbiota before and after antibiotics. Bacterial phyla abundance of untreated Muc2+/+ (lane a) and Muc2+/- (lane b) were similar, with a predominance of Bacteroidetes and Firmicutes. Antibiotics disrupted bacterial population (lanes b and d). (B) Alpha diversity showed equivalent species richness between Muc2+/+ and Muc2+/- littersmates, which differ in beta diversity between the 2 untreated genotypes was evident. Colonic tissues samples from Muc2+/- and Muc2+/- littersmates were analyzed by quantitative polymerase chain reaction for a comparison of proinflammatory cytokines and tight-junction protein expression before and after antibiotics. (D) Muc2+/- showed ongoing low-grade inflammation with significantly higher Il13 as compared with untreated Muc2+/+ littersmates. Antibiotics significantly decreased proinflammatory cytokines in Muc2+/-, (E) Antibiotic-treated Muc2+/- showed reduced constitutive intestinal permeability as measured by FITC dextran, with a correspondingly increase in (F) the tight junction proteins occludin and claudin 2. (G) Representative images of fluorescence in situ hybridization using the universal bacterial EUB338–Quasar 670 probe in mouse colonic tissue showing bacteria localization in the lumen. Ulex europaeus agglutinin lectin-FITC conjugated was used to visualize mucus. The section was counterstained with DAPI. In Muc2+/- bacteria (in red) is present within the mucus layer (green), whereas in Muc2+/- the absence of the mucus layer allowed bacteria to be in contact with the epithelium (white arrows). Scale bar = 50 µm. (H) Comparison of colonic lamina propria CD3+ T cells and CD19+ B cells at basal level. Muc2+/- presented with higher basal levels of T cells and lower CD19+ B cells at basal level. Muc2+/- – B cells at basal level.

Muc2+/+ But Not Muc2–/– Microbiota Is Required for Protection Against Dextran Sodium Sulfate–Induced Colitis

We next interrogated if mucus-associated (Muc2+/+) and non-mucus-associated (Muc2+/–) colonic microbiota played a protective role in susceptibility and resolution of dextran sodium sulfate (DSS)-induced colitis. We have previously shown17 that Muc2–/– littersmates are highly sensitive to DSS-induced colitis associated with high mortality and with a dosage of 1% DSS given orally for 3 days followed by water induced comparable weight loss and disease activity index (DAI) scores as Muc2+/+ receiving 3.5% DSS for 5 days. Based on these findings, we tested 3 different DSS treatment regime in Muc2–/– to quantify disease susceptibility: (1) 1% DSS for 3 days, (2) 1% DSS for 4 days, and (3) 1.5% DSS for 3 days followed by water. Muc2–/– given 1% DSS for 3 days lost 10% weight and slowly regained their weight up to 15 days. In comparison, Muc2+/– treated with 1% DSS for 4 days or 1.5% DSS for 3 days lost 20% of their body weight by day 8 and did not recover their weight up to 15 days (Figure 2A). Predictably, Muc2+/+– littersmates given 1% DSS for 3 days followed by water up to 10 days did not loss body weight, as was similar to the water control animals (Figure 2B). Thus, to induce equivalent levels of inflammation-driven weight loss in both genotypes, for all subsequent studies, Muc2–/– were treated with 1% DSS for 3 days and Muc2+/+ with 3.5% DSS for 5 days (see experimental regime in Figure 2C).

To investigate whether microbiota from Muc2+/+ and Muc2–/– littersmates conferred differential protective effects against colonic damage, animals were treated with antibiotics and challenged with DSS (Figure 2C). Surprisingly, Muc2+/+ but not Muc2–/– became highly susceptible to DSS-induced colitis and lost 10%-15% body weight as early as day 4, and by day 6, mortality rate reached 100% (Figure 2D). In contrast, antibiotic-treated Muc2–/– lost 10% body weight between days 7 and 9 (Figure 2E) with negligible mortality. Paradoxically, in mice lacking a mucus barrier alteration of microbiota was refractory against colonic injury. We hypothesized that low-grade inflammation in Muc2–/– littersmates was inducing a state of immune tolerance in the colon that limited severe injury. Interleukin (IL)-22 cytokine produced by intestinal innate lymphoid cells (ILCs) is implicated to induce immuno-tolerance in the gut28 and might be involved in conferring a protective role to Muc2–/– littersmates. To test this hypothesis, we isolated colonic LPLs from Muc2+/+ and Muc2–/– and determined IL-22 production by ILCs using flow cytometry. Basally, Muc2+/+ had higher productions of ILC3 positive for IL-22 as compared with Muc2–/– littersmates (Figure 2F). Moreover, antibiotics treatment increased IL-22+ ILC3 populations in Muc2–/– but not in in Muc2+/+ littersmates (Figure 2F). The significant increase of IL-22+ ILC3 population in antibiotic-treated Muc2–/– animals could explain why these mice had higher survival following DSS-induced colitis.
Microbiota From Muc2−/− Sensitizes the Colonic Mucosa of Muc2+/+ Littermates to DSS-Induced Colitis and Mortality

Gut microbiota from ulcerative colitis patients induce inflammation and increase susceptibility to colitis in naive animals. To investigate if dysbiotic Muc2−/− microbiota could induce inflammation and/or sensitize Muc2−/− littermates for increased susceptibility to colitis, fecal microbiota transplantation (FMT) was given to antibiotic-treated Muc2+/+ and Muc2−/− (homologous and heterologous) using stool from naive age- and sex-matched control animals (see experimental plan in Figure 3A). As revealed by 16s rRNA sequencing, gut bacterial dynamics was restored by FMT in both genotypes (Figure 3B). All FMT groups showed an increase in Bacteroidetes, and Proteobacteria in both genotypes receiving Muc2−/− FMT (Figure 3B). Nonmetric multidimensional scaling plot showed a clear shift in bacterial populations in both genotypes after antibiotic treatment and after receiving FMT (both homologous and heterologous) compared with untreated control animals (Figure 3C). To investigate if Muc2−/− microbiota was proinflammatory, animals were sacrificed on days 1, 5, and 10 after the last FMT and colon samples were analyzed for proinflammatory cytokine messenger RNA (mRNA) levels. Animals showed no significant change in body weight (Figure 3D) up to 10 days regardless of the FMT they received. Similarly, no significant difference in proinflammatory cytokine Il-1β or Ifn-γ mRNA levels was observed between groups. Muc2−/− receiving Muc2+/+ FMT showed a trend toward less proinflammatory cytokine expression, but the difference was only significant at day 1 (Figure 3E). Similarly, there was a trend in both genotypes receiving Muc2−/− FMT for higher inflammation. These results suggest that Muc2−/− microbiota per se is not colitogenic when transplanted into Muc2−/− littermates.

We next interrogated if FMT altered the susceptibility of the littermates toward DSS colitis. Surprisingly, Muc2+/+ receiving Muc2−/− but not Muc2+/+ FMT showed significantly higher mortality and impaired restitution at day 14 following DSS-induced colitis (Figure 4A). Muc2−/− receiving Muc2+/+ FMT showed little mortality and significantly regained body weights at days 12–14 (Figure 4A). Muc2+/+ FMT had no effect on Muc2−/− mortality or body weight upon DSS challenge (Figure 4B). This was confirmed by improved daily DAI (Figure 4C) and intestinal permeability on day 14 (Figure 4D). In contrast, Muc2+/+ receiving Muc2−/− FMT showed significantly higher DAI and increased intestinal permeability (Figures 4C and D).

To investigate the contribution of immune cells and/or gut microbiota as the prime cause for increased sensitivity toward DSS colitis, we generated bone marrow chimeras. Muc2+/+ receiving bone marrow from Muc2+/− littermates showed similar susceptibility toward DSS induced colitis as compared with Muc2+/+ receiving bone marrow from Muc2−/− (Figure 4E). These results confirm that increased susceptibility of Muc2−/− toward DSS is primarily due to the absence of intestinal mucus and has negligible effect on immune cells. In support of this, histopathology showed that compared with untreated Muc2+/+ (Figure 5A), and with Muc2+/+ receiving their own microbiota (Figures 5B, D, and F), colon samples of Muc2+/+ FMT with Muc2−/− microbiota (Figures 5C, E, and G) had significantly higher numbers of ulcerated lesions and damage to crypt architecture. At the height of acute disease on day 7 post-DSS regardless of the FMT, colonic tissues showed thicken muscularis and loss of crypts architecture with similar histological scores (Figures 5B, C, and H). Swiss roll tissue sections of Muc2+/+ receiving Muc2−/− microbiota showed marked damage throughout the colon length (Figure 5E), whereas Muc2+/+ FMT with their own microbiota presented with less damage in the proximal than the distal colon (Figure 5D). On day 14, Muc2+/+ receiving Muc2−/− FMT presented with worst histopathology scores (Figure 5H) characterized by thick muscularis and no signs of crypts regeneration (Figure 5G), whereas Muc2+/+ receiving their own FMT showed numerous crypts regenerating with epithelial cell proliferation (Figure 5F). While day 7 histopathology was comparable in Muc2+/+ irrespective of the FMT source, at day 14 of disease restitution, Muc2+/+ that received Muc2−/− FMT had significantly higher histological scores suggesting impaired recovery in surviving animals (Figure 5H). These results highlight that microbiota from Muc2−/− when transplanted to healthy host (Muc2+/+) increases disease susceptibility and impairs tissue healing and recovery following colonic injury.

Figure 2. (See previous page). DSS is lethal to antibiotic-treated Muc2+/+ but not Muc2−/− littermates. (A) Sensitivity of Muc2−/− littermates to different dosages of DSS. Animals were treated with different dosages of DSS and weight loss was examined. In all groups, approximately 10%–20% weight loss was observed, but recovery as assessed by weight gain was only evident in animals given 1% for 3 days. Each data point represents the mean ± SEM per animal group per day, n = 10 animals per group. (B) Muc2+/− are resistant to low dose DSS as compared with Muc2−/− littermates. Littermates were treated with 1% DSS (3d) after which DSS was replaced with tap water. DSS induced ~15% weight loss in Muc2−/− between day 6 and day 9 whereas Muc2+/− mice showed no weight loss. Each data point represents the mean ± SEM per group per day; control animals n = 3, Muc2+/− DSS n = 5, Muc2−/− DSS n = 10. (C) Diagrammatic work plan: briefly, Muc2+/− and Muc2−/− littermates received an antibiotic cocktail for 17 days and 1 day after were given DSS in drinking water. Muc2+/− received 3.5% DSS for 5 days while Muc2−/− received 1% DSS for 3 days, followed by ad libitum water. Mice were sacrificed on day 14 following DSS treatment. Control nonantibiotic-treated mice received the same % of DSS. (D) Antibiotic treated Muc2+/− were highly susceptible to DSS and lost weight faster and reached 100% mortality by day 6 as compared with untreated Muc2+/+ subjected to the same DSS regime. (E) In Muc2−/− littermates, no significant changes in DSS susceptibility were observed between animals that received antibiotics or not. (F) Isolated lamina propria cells from Muc2+/− and Muc2−/− littermates were characterized by flow cytometry. Muc2+/− ILC3 population was significantly increased after antibiotic treatment. IL-22 antibody was used to characterize ILC3 cell population. n = 4–6, *P < .05. BW, body weight.
A

Antibiotic treatment
Amphotericin-B [1 mg/kg]
Vancomycin [50 mg/kg]
Neomycin [100 mg/kg]
Metronidazole [100 mg/kg]
Ampicillin [1 mg/mL]

(24) 0 5 14
Muc2^{+/+} 3.5%
Muc2^{--} 1%
Water

B

Muc2^{+/+} Muc2^{--}

Relative abundance

Actinobacteria
Bacteroidetes
Deferrribacteres
Firmicutes
Fusobacteria
Proteobacteria
Tenericutes
Verrucomicrobia

FMT received

C

Muc2^{+/+} Muc2^{--}

NMDS2

NMDS1

Control
Abx treated
FMT Muc2^{+/+}
FMT Muc2^{--}

D

% BW change

Days

1 2 3 4 5 6 7 8 9 10

% BW change

Days

1 2 3 4 5 6 7 8 9 10

E

Il-1β mRNA

Time of sacrifice post-FMT

Relative expression

1d 5d 10d

Il-1β mRNA

Time of sacrifice post-FMT

Relative expression

1d 5d 10d

Tnf-α mRNA

Time of sacrifice post-FMT

Relative expression

1d 5d 10d

Ifn-γ mRNA

Time of sacrifice post-FMT

Relative expression

1d 5d 10d
Presence of Tolerogenic Immune Cells in Colonic Lamina Propria of Muc2−/− Littermates

Given that Muc2−/− has low-grade ongoing inflammation and its microbiota increases disease susceptibility to Muc2+/+ littermates, we next explored the mechanisms through which Muc2−/− tolerate their microbiota to cope with basal inflammation. A recent study21 suggested that Muc2−/− develop spontaneous colitis due to a reduction in CD103+ CD11b+ and an increase in CD103− CD11b+ dendritic cells (DCs) population. Based on this, we characterized the immune cell populations. Under basal conditions, Muc2−/− littermates presented with significantly higher levels of CD45+ MHCI+ cell populations (Figures 6A and B). Cells were gated based on CD11b and CD11c expression (Figures 6A and C). These cells are predominantly phagocytes that help clear incoming microbial penetrants at the colonic surface. We also observed increased levels of colonic CD103+ CD11c+ (R1) DCs population in Muc2−/− littermates (Figures 6C–E), which may potentiate the development and proliferation of T regulatory cells (Tregs). In support of this, we quantified CD4+ FoxP3+ cells in small intestine and colonic LPLs and observed that basally, Muc2−/− exhibited higher populations of CD4+ FoxP3+ Tregs as compared with Muc2+/+ (Figure 6F). To confirm a role for Tregs in maintaining the Muc2−/− inflammatory phenotype in-check, we neutralized Tregs effector molecules IL-10 and transforming growth factor β (TGF-β), which have potent anti-inflammatory effects. Muc2−/− mice lost weight rapidly after injection of anti-IL-10 and anti-TGF-β antibodies and by day 5 post-injection, their weight loss was significantly lower compared with Muc2+/+ (Figure 6G). Five days after injection, Muc2+/+ treated and control animals showed no visual differences whereas, treated Muc2−/− mice presented with watery stool consistency and shorter and thicker colons (Figure 6H). This was accompanied with higher mRNA expression for proinflammatory cytokines Il-1β and Ifn-γ (Figure 6I) as well as myeloperoxidase activity (Figure 6J) as compared with untreated control animals. These results clearly show that the intestinal microbiota in Muc2−/− littermates induces the recruitment of tolerogenic immune cells at colonic sites that allow them to mitigate the damage caused by an inflammatory phenotype.

The Impact of Muc2−/− Microbiota Could Be Explained Through Operational Taxonomic Units From Distinctive Families That Are Transplantable to Muc2+/+ Littermates

To determine if the biologic effects seen with Muc2−/− microbiota over Muc2+/+ littermates was associated with a putative bacterium group, we performed 16S rDNA-sequencing analysis on day -17 (before antibiotics) and on days 1, 5, and 10 after receiving antibiotics and all 3 FMT (Figures 7A–G). On day 1, both Muc2+/+ and Muc2−/− FMT with their own microbiota (Figure 6A, blue circles in panels b and c) displayed a bacterial composition similar to their preantibiotics state (red circles). However, at this same time point (day 1), a difference in composition was noticeable in Muc2−/− receiving Muc2−/− FMT (Figure 7A, panel a) and especially contrasting in Muc2+/+ receiving Muc2−/− FMT (Figure 7A, panel d) that corresponded with a significant drop in alpha diversity in Muc2−/− at day 1 after receiving Muc2−/− FMT (Figure 8A). When compared with their pre-antibiotics state, these differences are not maintained throughout time since the diversity returns to a more similar preantibiotics state as soon as 5 days after the last FMT and alpha diversity was similar among treatments (Figure 7A). Based on these results, we next compared microbiota composition between both FMT in Muc2+/+ (FMT with Muc2−/− vs FMT with homologous) at day 1. Results revealed differences in bacterial composition with those receiving Muc2+/− FMT having up to 6 times more operational taxonomic units (OTUs) from Enterobacteriaceae and higher amounts of the Verrucomicrobiaceae family (Figure 8B). In contrast, there was a decrease in OTUs from some Proteobacteria families such as Pseudomonadaceae and Desulfovibrionaceae. OTUs from the Anaeroplasmataceae and Deferribacteraeaceae families were also decreased, along with some Firmicutes families such as Ruminococcaceae, Lactobacillaceae, Lachnospiraceae, and Bacteroidaceae and some Bacteroidetes families like Prevotellaceae, Rikenellaceae, and particularly S24-7 experienced a decrease in their populations when compared with the ones FMT with Muc2−/− microbiota (Figure 8B).

OTUs among both FMT in Muc2+/+ were grouped by family, and the 5 most abundant were plotted to contrast their abundance per FMT treatment and time points (Figure 7B), these being Bacteroidaceae, Lactobacillaceae, S24-7, Enterobacteriaceae, and Verrucomicrobiaceae families. At day 1 post-FMT, a dramatic difference between both FMT treatments was observed, where Muc2+/+ FMT with Muc2−/− showed increase abundance in members of the Bacteroidaceae family (Figures 7B and C), as well as members of the Enterobacteriaceae family (Figures 7B and F) and Verrucomicrobiaceae (Figures 7B and G). In contrast, members of the Lactobacillaceae (Figures 7B and D) and the

Figure 3. (See previous page). C57BL/6 and in-house Muc2−/− have different bacteria phyla distribution. (A) Diagrammatic work plan. Briefly, Muc2+/+ and Muc2−/− antibiotic-treated mice received FMT every other day before giving DSS in drinking water. Muc2+/+ received 3.5% DSS for 5 days while Muc2−/− received 1% DSS for 3 days, followed by ad libitum water. Mice were sacrificed on day 14 following DSS treatment. (B) The 16s rRNA sequencing comparison of bacterial phyla abundance in Muc2+/+ and Muc2−/− littermates receiving either homologous or opposite genotype FMT. Analysis shows the results of day 1 post-FMT. (C) Nonmetric multidimensional scaling (NMDS) analysis of samples was performed to plot population distribution between each sample, in which a clear separation between groups is seen. (D) Muc2−/− and Muc2+/+ mice were treated for 17 days with an antibiotic cocktail and received FMT with either Muc2−/− or Muc2+/+. Animals were sacrificed 1, 5, and 10 days after FMT. No significant differences in weight change were observed between the 4 groups. (E) Muc2−/− receiving Muc2−/− FMT showed no significant increase in proinflammatory cytokines compared with control animals receiving their own FMT. Relative expression as compared with its own untreated control animal. n = 3–4, *P < .05, **P < .01. Abx, antibiotics; BW, body weight.
Figure 4. Muc2\(^{-/-}\) FMT increases susceptibility to DSS-induced colitis in Muc2\(^{+/+}\) littermates. (A) Antibiotic treated Muc2\(^{+/+}\) receiving Muc2\(^{-/-}\) FMT showed increased mortality to DSS induced colitis and the surviving animals did not recover weight up to day 14. (B) Muc2\(^{-/-}\) mice receiving Muc2\(^{+/+}\) FMT showed less severe illness and no mortality in response to DSS induced colitis. (C) Muc2\(^{+/+}\) mice receiving Muc2\(^{-/-}\) FMT showed an increased in DAI compared with those who received their own. (D) On day 14, Muc2\(^{-/-}\) receiving Muc2\(^{+/+}\) FMT showed increased intestinal permeability as compared with Muc2\(^{+/+}\) receiving their own microbiota. (E) Survival and body weight change of Muc2\(^{+/+}\) and Muc2\(^{-/-}\) bone marrow (BM) chimeras challenged with DSS. n = 4–6, \(* P < .05, \,** P < .01,\) BW, body weight.
S24-7 family were reduced in these mice (Figures 7B and E). Muc2−/− FMT with their own microbiota also showed an increase in the Bacteroidaceae (Figure 7C), Enterobacteriaceae (Figures 7F), and Verrucomicrobiae (Figure 7G) families. It is noteworthy that these changes in bacterial dynamics are not permanent, because 10 days after the last FMT the differential abundance came back to their normal state. These results give strong evidence that these bacteria played a primordial role in mucosal sensitization to DSS when Muc2+/+ received Muc2−/− FMT.

We also used phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt) to predict metabolic differences and to identify their potentially distinctive functional features among the samples. Metagenomes were predicted from the 16S rRNA data and differences were focused in Muc2+/+ receiving either Muc2−/− or their own FMT (Figure 9). Among them, important pathways related with gram-negative pathogens are proposed to be up regulated in those receiving Muc2−/− FMT, such as genes involved in biofilm of E. coli, Pseudomonas aeruginosa, and Vibrio cholerae, as well as genes related to lipopolysaccharide biosynthesis, flagellar assembly, and glutathione metabolism (Table 1). Genes that were downregulated in Muc2+/+ receiving Muc2−/− FMT included some involved in methane, carbon, and butyrate metabolism. Therefore, we were interested in exploring the contributions of taxa to each of the predicted pathways across the sample groups. Several families within different phylum were related to those predicted changes in the metagenome. Bacteroidetes family S24-7 was represented in high proportion among all pathways, both up- and downregulated and at different time points and FMT treatments. Likewise, the Bacteroidaceae family was also present among up- and downregulated pathways throughout all the samples but is less represented than S24-7. Interestingly the family Enterobacteriaceae was also present in both up- and downregulated pathways, but with a noticeable increase to the pathway contribution at day 1 after FMT with Muc2−/− microbiota (Figure 9, Table 1).

**Discussion**

Gut microbiota is essential to human health and mucus provides them with a niche and food source to thrive. Dysbiosis and depletion of mucus have been implicated with colonic inflammation and IBD. Thus, understanding the distinct roles of the microbiota in the presence or absence of the mucus bilayer in innate host defense is critical in understanding disease pathogenesis. In this study we have revealed shifts in microbial populations in the absence of a mucus layer. These bacteria were found in direct contact with the epithelium that elicited low-grade inflammation that was counteracted with an increase in immune tolerogenic cells. In turn, this microbiota when transplanted into WT littermates sensitized their mucosa for increased intestinal injury.

The role of mucus layer in development and regulation of the immune system is increasingly recognized as it separates gut bacteria from intestinal immune cells. In IBD, commensal bacteria are the target of host immune aggression, thus triggering an inflammatory phenomena and perpetuating mucosal destruction. Our study shows that close contact of bacteria with the intestinal epithelium creates a proinflammatory milieu evidenced by increased levels of Tnf-α and Il-1β that in turn potentiated intestinal permeability. Surprisingly, however, was that antibiotic-treated Muc2−/− showed no severity to DSS-induced mortality whereas Muc2+/+ littermates succumb to the injury emphasizing the protective role of gut microbiota for proper functioning of immune system. IL-22 cytokine, mainly released by ILC3, plays a key role in maintaining gut-microbial homeostasis, epithelial barrier function and stimulating tissue repair in the colon. The IL-3-IL-22 axis has also been found to be important in regulating immune response against extracellular pathogens (bacteria and fungus), as well as preventing their translocation through the stimulation of antimicrobial peptides, reviewed in Geremia and Arancibia-Cárcamo. A link between IL-22 and Muc2 has been suggested, however, the exact mechanism and how it is regulated it is not yet fully understood. Higher levels of IL-22 have been reported in the ileum of Muc2−/− mice. We theorize that high levels of ILC3-IL-22 in Muc2−/− littermates induced a tolerance state that allowed them to cope with ongoing mild inflammation without developing fulminant colitis.

Mucosal tolerance is critical in maintaining intestinal homeostasis, and to provide an immune exclusion state against commensal microbiota. This is mainly maintained by lamina propria DCs as they sample the microbial content and stimulate Tregs to produce anti-inflammatory IL-10 and TGF-β. We observed the presence of higher number of CD45+ MHCI+ phagocytic cells in the lamina

---

**Figure 5.** (See previous page). Muc2+/+ receiving Muc2−/− FMT impaired tissue healing and crypts regeneration following DSS-induced colitis. (A) Representative images of hematoxylin and eosin–stained Swiss-rolled colons from untreated control showing normal architecture with crypts filled with goblet cells. (B, D, and F) Muc2+/+ receiving Muc2+/+ FMT and (C, E, and G) Muc2+/+ receiving Muc2−/− FMT. Note loss of crypts architecture, ulcerated lesions and thickness of the muscularis in both (B) Muc2+/+ receiving Muc2+/+ FMT and (C) Muc2+/+ receiving Muc2−/− FMT microbiota at day 7. (D) Swiss roll sections showed that Muc2+/+ receiving Muc2+/+ FMT lesions were restricted to the mid and distal colon. (E) Muc2+/+ receiving Muc2−/− FMT showed more intense tissue damage with complete loss of crypts and damage throughout the length of the colon. (F) In contrast, at disease resolution on day 14, Muc2+/+ receiving Muc2+/+ FMT showed crypts restitution and epithelial cell proliferation with a normal muscularis, (G) while no crypts regeneration and a thick muscularis were predominant in Muc2+/+ receiving Muc2+/+ FMT. Scale bar = 50 μm in A, B, C, F, and G. Scale bar = 200 μm in D and E. (H) Blinded histologic score values at days 7 and 14 post-DSS. At day 7, the histologic score was comparable between both groups, however, at disease recovery phase on day 14, Muc2+/+ receiving Muc2+/+ FMT had significantly higher histologic scores than the group that received homologous FMT. n = 10, *P < .05.
propria of Muc2−/− than in Muc2+/+ littermates. This, no doubt exerted a protective effect as Muc2−/− had higher gut microbial penetrants in the absence of a mucus barrier. Similarly, we also found increased populations of colonic CD103+CD11c+ DCs in Muc2−/−, critical for establishing tolerance and to withstand ongoing low-grade colonic inflammation.31 Because differences in microbial dynamics present in untreated animals would not reflect the bacteria that are transplantable, we identified differences between both FMT groups (homologous and heterologous) in Muc2+/+ littermates. We found that the Bacteroidaceae family was significantly increased in both genotypes receiving Muc2+/+ microbiota, particularly in Muc2−/− recipients (4-fold increase). Bacteroides is a clinically relevant group of bacteria and includes many known pathogens having unique secretion systems, endotoxins and virulence factor genes that provides them antimicrobial resistance.35,46 A recent study using Muc2−/− mice, linked the genus Bacteroides to susceptibility toward DSS-induced colitis and altered gene expressions associated with bacteria sensing and stress response.47 OTUs from the family Verrucomicrobiaceae were significantly increased within both genotypes receiving Muc2+/+ FMT. This family is of special interest as it includes the mucin degrading bacteria Akkermansia muciniphila, a commensal associated with maintaining homeostasis. Their reduced levels have been reported in patients with IBD and various metabolic disorders.48 We also noticed a reduction in OTUs of Lactobacillaceae family, which are lactic acid–producing bacteria and considered as important probiotics for their positive effects on host health.49,50 Recently,51 it was established that within the first 3 weeks of colonization, the gut bacterial population goes through a series of changes until becoming stable, making evident the dynamics of microbiota population after being transferred to a new host.

PICRUSt is a valuable bioinformatics tool that allows to make predictions of gene and/or metabolic pathways that might be over or under-expressed.52 Table 1 summarizes the predicted metabolic pathways that were significantly different between microbiota within Muc2+/+ receiving either Muc2−/− or homologous FMT. We observed upregulated pathways that were related to gram-negative pathogens, such as genes involves in biofilm formation of V. cholerae, E. coli, and P. aeruginosa. Biofilm formation plays an important role in bacterial infections, sheltering them from the host immune defense and allowing them to attach, proliferate and spread inside of the host.52 Similarly, we observed upregulation of genes involved in glutathione metabolism. Within bacteria, glutathione is only present in Cyanobacteria and Proteobacteria and is used as a protecting mechanism in different stress triggers such as low pH and oxidative stress. In addition, up regulation of genes involved in lipopolysaccharide biosynthesis were also predicted. The up regulation of these pathways correlates and could be explained due to a higher relative abundance of gram-negative Proteobacteria, particularly family Enterobacteriaceae in Muc2+/+ receiving Muc2+/+ FMT.

In summary, we have identified a distinctive gut microbiota in Muc2−/− littermates in the absence of mucus that maintains a constitutive proinflammatory milieu in their colon. This unique microbial population did not trigger basal proinflammatory responses when transplanted into Muc2+/+ littermates but rather, sensitized the colonic mucosa for increased sensitivity toward DSS-induced colitis. Unlike Muc2−/−, Muc2+/+ microbiota played a protective role against chemical-induced colitis that was lost following antibiotic treatment. A limitation of the study is that despite the phenotypic effects of the different treatments being comparable in Muc2+/+ vs Muc2−/−, it is difficult to ascertain the difference in immune response and microbiota changes as those effects may be independent of the level of inflammation induced and could be a direct effect of the drug itself. We conclude that both the colonic mucus layer and indigenous microbiota play key roles in conferring innate resistance against colonic injury and homeostasis.

Materials and Methods

Ethics Statement and Animals

Eight- to 12-week-old male and female C57BL/6 and Muc2+/+ mice were used. C57BL/6 mice were obtained from Charles River Laboratories (Saint-Constant, Quebec, Canada), while Muc2−/− of the same genetic background was bred in house. Animals were backcrossed to generate Muc2−/+ breeding pairs to derive Muc2+/−/+ and Muc2−/− littermates that were used for the experiments. All animals were housed under specific pathogen–free conditions in...
Table 1. PICRUSt Prediction of Significantly Different Metabolic Pathways Between Muc2\textsuperscript{+/−} FMT With Muc2\textsuperscript{−/−} or Homologous Microbiota

| Pathway                                           | KEGG ID   | P value  | Adjusted P value | Normalized enrichment score |
|---------------------------------------------------|-----------|----------|------------------|----------------------------|
| Biofilm formation - Vibrio cholerae               | map05111  | 2.5 × 10\textsuperscript{−5} | .0014            | 2.2                        |
| Biofilm formation - Escherichia coli              | map02026  | 2.6 × 10\textsuperscript{−5} | .0014            | 2.1                        |
| Staphylococcus aureus infection                   | map05150  | 7.1 × 10\textsuperscript{−5} | .0017            | −2.6                       |
| Aminoacyl-tRNA biosynthesis                       | map00970  | 7.9 × 10\textsuperscript{−5} | .0017            | −2.2                       |
| Lipopolysaccharide biosynthesis                   | map00540  | 8.0 × 10\textsuperscript{−5} | .0017            | 1.9                        |
| Ribosome                                          | map03010  | 9.9 × 10\textsuperscript{−5} | .0018            | −2.7                       |
| Methane metabolism                                | map00680  | .00012   | .0018            | −2.7                       |
| Carbon metabolism                                 | map01200  | .00029   | .0039            | −1.8                       |
| Biosynthesis of siderophore group nonribosomal peptides | map01053  | .00088   | .0099            | 1.8                        |
| Flagellar assembly                                | map02040  | .00092   | .0099            | 1.8                        |
| Carbon fixation pathways in prokaryotes           | map00720  | .0035    | .032             | −1.6                       |
| Cationic antimicrobial peptide (CAMP) resistance  | map01503  | .0041    | .034             | 1.7                        |
| Glutathione metabolism                            | map00480  | .0052    | .038             | 1.7                        |
| Biofilm formation - Pseudomonas aeruginosa        | map02025  | .0052    | .038             | 1.6                        |
| Butanolate metabolism                             | map00650  | .0061    | .041             | −1.5                       |

FMT, fecal microbiota transplantation; KEGG, Kyoto Encyclopedia of Genes and Genomes; PICRUSt, phylogenetic investigation of communities by reconstruction of unobserved states.

DSS-Induced Colitis

Colitis was induced using DSS (MW: 36,000–50,000; MP Biochemicals, Santa Ana, CA) dissolved in tap water. Muc2\textsuperscript{−/−} animals received 1% for 3 days, while Muc2\textsuperscript{+/−} mice received 3.5% for 5 days follow up by water ad libitum as previously described. The cumulative DAI was scored based on weight loss, stool consistency, blood loss, and appearance as previously described.

OTU Table Construction

Raw reads were processed with cutadapt 1.8.3\textsuperscript{53} to remove the primer sequences and any preceding adaptors. Subsequent processing was done using the UPARSE pipeline\textsuperscript{54} as implemented in usearch 8.1.1861. The forward and reverse reads were merged using the fastq_mergepairs option of usearch and subsequently filtered with usearch -fastq_filter and an expected error cutoff of 0.5. The filtered reads were de-replicated using usearch -derep_fulllength and then clustered with usearch -cluster_otus and the option ‘-minsize 2’ to remove singleton reads prior to clustering. Taxonomy was assigned to the representative sequences using the RDP-naive Bayesian classifier\textsuperscript{56} with May 2013 version of the Greengenes database. The final OTU table was constructed with usearch -search_global and the options ‘-strand plus -id 0.97’. The entire procedure was run as a Snapemake pipeline.

Fecal Microbiota Transplantation

FMT was achieved by collecting 0.1 g of fresh feces (about 4 fecal pellets), homogenizing in 1 mL of sterile phosphate-buffered saline and centrifuged for 30 seconds at 1000 g. Each mouse was gavaged 3 times with 200 μL of the obtained supernatant every 48 hours.

Figure 7. (See previous page). Muc2\textsuperscript{−/−} microbiota transplanted to Muc2\textsuperscript{+/−} littersmates. (A) Dissimilarity measured by nonmetric multidimensional scaling (NMDS) illustrates the distance throughout samples that were antibiotic-treated and FMT with Muc2\textsuperscript{−/−} and Muc2\textsuperscript{+/−} microbiota. Time points are as follow: day −17: before antibiotic treatment, days 1, 5, and 10 correspond to days passed after the last FMT; (a) Muc2\textsuperscript{−/−} FMT with Muc2\textsuperscript{+/−}, (b) Muc2\textsuperscript{+/−} FMT with Muc2\textsuperscript{−/−}, (c) Muc2\textsuperscript{−/−} FMT with Muc2\textsuperscript{+/−}, and (d) Muc2\textsuperscript{+/−} FMT with Muc2\textsuperscript{−/−}. (B) Significantly different OTUs between Muc2\textsuperscript{+/−} FMT with Muc2\textsuperscript{+/−} and Muc2\textsuperscript{+/−} were grouped by family and the top 5 plotted in a bar graph to illustrate their difference in abundance. Plots C–G display the 5 families’ dynamics at different time points.
Figure 8. Fecal transplant of Muc2\(^{-/-}\) into Muc2\(^{+/+}\) changes bacteria family abundance and decreases their alpha diversity. (A) Alpha diversity of Muc2\(^{+/+}\) and Muc2\(^{-/-}\) was characterized by Shannon’s index in Muc2\(^{+/+}\) and Muc2\(^{-/-}\) littermates at different time points; before antibiotic treatment (day -17), and 1, 5, and 10 days after receiving the last FMT (day, 1, 5, and 10, respectively). Notice the drop in species diversity in the Muc2\(^{+/+}\) group at day 1 after FMT with Muc2\(^{-/-}\) microbiota. Wilcoxon rank sum test for differences in Shannon diversity between Muc2\(^{+/+}\) treatment and Muc2\(^{-/-}\) treatment. \(P\) values are adjusted for multiple testing using the Benjamini and Hochberg method. (B) Differential abundance, at the family level, between Muc2\(^{+/+}\) FMT with Muc2\(^{+/+}\) and Muc2\(^{-/-}\) microbiota based on 16S rDNA from Muc2\(^{+/+}\) FMT with either Muc2\(^{+/+}\) or their own microbiota. Results are shown as fold-change in Muc2\(^{+/+}\) FMT with Muc2\(^{-/-}\) relative to Muc2\(^{+/+}\) FMT with Muc2\(^{+/+}\). Log2 fold-changes are plotted for significantly different (\(P < .05\)) family for each of the comparisons. ***\(P < .001\).
Diversity Analysis

Downstream analysis was done in R 3.3.1\textsuperscript{58} using phyloseq 1.16.2\textsuperscript{59} and vegan 2.4-1.\textsuperscript{60} Mitochondrial and chloroplast sequences were removed along with OTUs that appeared only in 1 sample. Samples with <1000 sequences were also removed from the analysis. Alpha-diversity was measured using the Shannon index.\textsuperscript{61} Differences in alpha diversity between groups was tested using a Wilcoxon rank sum test, controlling the false discovery rate\textsuperscript{62} and using a cutoff of \( P < .05 \) for rejecting the null hypothesis of no difference between groups. Between-sample diversity was evaluated using the Bray-Curtis distance metric on proportionally normalized OTU counts and visualized with nonmetric multidimensional scaling. The generalized linear model framework as implemented in DESeq2\textsuperscript{63} was used to identify OTUs in the \textit{Muc2}\textsuperscript{+/+} group that were differentially abundant between \textit{Muc2}\textsuperscript{+/+} FMT with \textit{Muc2}\textsuperscript{−/−} or with homologous microbiota. Day –17: untreated control, day 1: 1 day after the last FMT.

\textbf{Figure 9. Relative contribution of bacterial families to predicted metagenome in \textit{Muc2}\textsuperscript{+/+}.} This figure illustrates the main families that contained the genes involved in the predicted metagenome resulted from PICRUSt in \textit{Muc2}\textsuperscript{+/+} mice FMT with homologous or \textit{Muc2}\textsuperscript{−/−} microbiota. Bacteria family contribution to PICRUSt-predicted pathways are significantly different between \textit{Muc2}\textsuperscript{+/+} FMT with \textit{Muc2}\textsuperscript{−/−} or with homologous microbiota. Day –17: untreated control, day 1: 1 day after the last FMT.
**Metagenome Predictions**

Metagenomes were predicted using PICRUSt 1.1.23 using a closed reference based OTU table constructed with QIIME 1.9 using the “pick_closed_reference_otus.py” script with default settings.66 Gene predictions were generated for KEGG (Kyoto Encyclopedia of Genes and Genomes) orthologs and these predictions were then used as input for HUMAnN2, which was used to calculate taxonomic contribution to functions. Log2 fold-changes between Muc2+/+ and Muc2−/− FMT-treated at Day1 (same model as for the OTU data) were estimated with DESeq2 and used to identify enriched pathways with gene set enrichment analysis66 as implemented in clusterProfiler 3.2.14.67

**DNA Extraction and 16S rRNA Gene Sequencing**

DNA extraction of fecal samples or tissues were carried out using a previously described protocol that enhanced DNA recovery from microbial communities with modifications30 to increase quantitative recovery of bacteria across different taxa (enzymatic pretreatment with mutanolysin, lysozyme, and proteinase K). Paired end reads of the V3 region of the 16S rRNA gene using bar coded Illumina lysozyme, and proteinase K). Paired end reads of the V3 region of the 16S rRNA gene using bar coded Illumina sequencing as described previously69 with the modification that barcodes are included in the forward primer. A total of 250 nucleotides paired-end sequences were carried out on a MiSeq Illumina sequencer (Illumina, San Diego, CA) providing complete overlapping sequence reads of the V3. These overlaps are used for correcting poor quality base calls and increasing sequencing accuracy. A total of 30–60,000 16s RNA reads were generated per sample.

**Intestinal Permeability**

FITC dextran was used to examine intestinal permeability. Briefly, mice were gavaged with 8-mg FITC-dextran (3–5 kDa; Sigma Aldrich, St Louis, MO); 3 hours later, mice were anesthetized by isoflurane (Pharmaceutical Partners of Canada, Richmond Hill, Ontario, Canada), and blood was collected by cardiac puncture and animals sacrificed by cervical dislocation. Whole blood was allowed to clot in the dark for 3 hours at room temperature and centrifuged at 10,000 g for 10 min. Serum was transferred to a clean Eppendorf tube and diluted with an equal volume of phosphate-buffered saline. An aliquot of 100 μL of each sample was loaded onto a black bottom 96-well plate in duplicate, and fluorescence was determined with a plate reader (absorption 485 nm, emission 535 nm). This magnitude is expressed in relative fluorescence units.

**Histology and Staining**

At the endpoint of the experiments, animals were anesthetized and sacrificed by cervical dislocation and the colon was excised. The colon was opened longitudinally along the mesenteric border and rolled distal to proximal end to form a Swiss roll. The Swiss roll was sectioned in half with one portion being used for histological analysis and the other one used for gene expression analysis. For histology, colonic tissues were fixed in Carnoy’s solution, and embedded in paraffin blocks. The 7-μm tissue sections were rehydrated through an ethanol gradient to water and stained with hematoxylin and eosin (EMD Chemicals, Gibbstown, NJ) to examine overall tissue morphology and Periodic acid Schiff reagent (PAS; Sigma-Aldrich) to visualize neutral mucins. Histologic score was measured as previously described.22

**Bacterial Localization**

Fluorescence in situ hybridization was performed as described previously.70 Briefly 5 μm sliced Carnoy’s fixed tissue was incubated with the total bacteria probe EUB338 5′-GCT GCC TCC CGT AGG AGT-3′ ([50 ng/μL] coupled with Quasar 670 dye at 46 °C overnight. FITC coupled-Ulex europaeus agglutinin was used at [1:1000] to visualize the fucosylated residues in mucins and DAPI [1:1000] (Life

---

**Table 2. Primer Sequences Used for Quantitative Real-Time Polymerase Chain Reaction**

| Name       | Sequence 5′→3′ | Annealing temperature (°C) | Reference |
|------------|---------------|----------------------------|-----------|
| 16s V6     | Fwd: AGGATTAGATACCCTGGTA Rev: CRRGAGAGCTGACG         | 55          | 23        |
| IL-1β      | Fwd: GCCTCGTGTGTCGAGCCCA Rev: CTGCAGGGTGGGTGTGC         | 65          | 20        |
| TNF-α      | Fwd: ATGAGGACAGAAAGAGTATGAC Rev: TACAGCGTTGACTGAGATATTTC | 56          | 73        |
| IFN-γ      | Fwd: TCGGAAGGATGGAAGAAAGA Rev: TGGCTGTGACGAGTTTTCATG    | 54          | 73        |
| Occludin   | Fwd: AGAGGCTATGGGACAGGGCTTTTGGG Rev: CCAACAGGAAAGCTCTGGCTTGG | 60          | 74        |
| Claudin-2  | Fwd: CTCGCGTATGGTATATCTCTG Rev: GAGTAGAAAGCTCCAGAGGA    | 60          | 74        |
| Actin      | Fwd: CTACAAATGAGCTGCTGTTG Rev: TGGGCTTTGAAAGGTGCT       | 54          | 20        |

IFN, interferon; IL, interleukin; TGF, transforming growth factor.
Technologies, Carlsbad, CA) for nuclear counterstain. Tissue sections were visualized using an Olympus FV1000 scanning confocal inverted microscope (Olympus, Tokyo, Japan).

**Gene Expression Analysis**

Total RNA was isolated from snap-frozen tissue using the Trizol reagent method (Invitrogen; Life Technologies) as per manufacturer’s specifications, and the yield and purity determined by the ratio of absorbance at 260/280 nm (NanoDrop; Thermo Fisher Scientific, Waltham, MA); only samples with a ratio of ~1.8 for DNA and ~2.0 for RNA were used. RNA from DSS-treated mice tissue was reprecipitated with lithium chloride precipitation solution (Ambion; Life Technologies). Complementary DNA (cDNA) was prepared using a qScript cDNA synthesis kit. Real-time quantitative polymerase chain reaction was performed using a Rotor Gene 3000 real-time polymerase chain reaction system (Corbett Research, Sydney, Australia). Each reaction mixture contained 100 ng of cDNA, SYBR Green polymerase chain reaction Master Mix (Qiagen, Hilden, Germany), and 1 µM of primers. A complete list of the primer sequences and conditions used are listed in Table 2. The results were analyzed using the 2-ΔΔCT method and expressed as fold changes.

**In Vivo IL-10 and TGF-β Neutralization**

*Muc2*+/− and *Muc2*−/− littermates received intraperitoneally 500 µg of each antibody: anti-TGF-β (BioXcell, BE0057) and anti-IL-10R (BioXcell, BE0050). Mice were sacrificed 5 days postinjection and colon and serum were collected for colitis inflammatory parameters assessment. Mice were weighed every 24 hours and monitored throughout the duration of the experiment.

**Myeloperoxidase Assay**

Myeloperoxidase activity in mouse colon samples (50 mg of fresh-frozen tissues) was measured as a marker for neutrophil influx as previously described. Briefly, tissue was homogenized in 0.5% hexadecyltrimethylammonium bromide in 50-mM phosphate buffer (pH 6.0). Homogenized tissue was freeze-thawed 3 times, sonicated, and centrifuged (10,000 g for 10 minutes at 4 °C) and supernatant was collected. The reaction was initiated by addition of 1-mg/mL dianisidine dihydrochloride (Sigma-Aldrich) and 1% H2O2. Change in optical density was measured at 450 nm.

**LPLs Isolation**

Animals were euthanized at the end of the experiment, and the colon was surgically removed to isolate LPLs using an established protocol. In brief, colon was longitudinally cut open and cleaned for any fecal matter using HBSS. Then, it was cut into small 2- to 3-cm pieces to dissociate epithelial cells using Hank’s Balance Salt Solution containing EDTA and DTT in a 50-mL falcon tube and placed in an incubator shaker at 37 °C for 20 minutes. Supernatant was discarded and remaining tissue was digested with collagenase to obtain LPLs.

**Generation of Bone Marrow Chimeric Animals**

A single dose of 9.50 Gy was given to *Muc2*+/− and *Muc2*−/− littermates 6–8 weeks old and reconstituted with 5 × 10^5 bone marrow cells per animal within 5 hours intravenously. Animals were given 2-g/L neomycin sulfate ad libitum for 3 weeks and then intestinal microbiota was reconstituted using FMT. FMT were done 3 times 3 days apart and experiments were carried out 10 days after last FMT.

**Flow Cytometry**

LPLs were isolated and stimulated with Phorbol 12-myristate 13-acetate and ionomycin in the presence of brefeldin and monensin for 4 h at 37 °C in a humidified CO2 incubator. Stimulated cells were stained for surface antigens with fluorescently labelled antibodies. Cells were then stained with fixable viability dye FV510 for live/dead discrimination followed by intracellular staining using Fix/Perm transcription factor kit (BD Biosciences, Franklin Lakes, NJ) and fluorescently labeled antibodies as follows: IL4 - PE-Cy7 (560699; BD Pharmingen, Franklin Lakes, NJ), KLRG1 – PerCP-Cy5.5 (563595; BD Pharmingen), IL22 – PE (BD Pharmingen; 516404), IFNγ- APC-Cy7 (561479; BD Pharmingen), Ly6G- FITC (BD Pharmingen; 561105), NK1.1 -FITC (561082; BD Pharmingen), CD3- FITC (561798; BD Pharmingen), CD19- FITC (BD Pharmingen; 561740), B220- FITC (561877; BD Pharmingen), Nkp46- AF700 (561169; BD Pharmingen), RORγt- AF647 (562682; BD Pharmingen), viability dye FV510- BV510 (BD Pharmingen; 564406), CD127- BV421 (566377; BD Pharmingen), and CD45- BV786 (565477; BD Pharmingen). For Tregs quantification, Mouse Th17/Treg Phenotyping Kit (BD Biosciences) was used. Data were acquired on BD FACSCanto flow cytometer and analyzed using FlowJo software (FlowJo, Ashland OR).

**Statistical Analysis**

Data were analyzed using GraphPad Prism 6 (GraphPad Software, San Diego, CA) for all statistical analysis. Treatment groups were compared using analysis of variance when more than 2 groups were compared. Student’s t test was used when only 2 groups were compared. Statistical significance was assumed at P < .05. Error bars in all the graphs represent mean ± SEM.

**References**

1. O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006;7:688–693.
2. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Reddy DN. Role of the normal gut microbiota. World J Gastroenterol 2015;21:8778–8803.
3. Palm NW, de Zoete MR, Flavell RA. Immune–microbiota interactions in health and disease. Clin Immunol 2015;159:122–127.
4. Guerner F. Decade in review—gut microbiota: The gut microbiota era marches on. Nat Rev Gastroenterol Hepatol 2014;11:647–649.
5. Peterson CT, Sharma V, Elmén L, Peterson SN. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin Exp Immunol 2015;179:363–377.
6. Franzosa EA, Huang K, Meadow JF, Gevers D, Lemon KP, Bohannan BJM, Huttenhower C. Identifying personal microbiomes using metagenomic codes. Proc Natl Acad Sci 2015;112:E2930–E2938.

7. The Human Microbiome Project. Structure, function and diversity of the healthy human microbiome. Nature 2012;486(7402):207–214.

8. Marchesi JR, Adams DH, Fava F, Hermes GDA, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tuohy KM, Thomas LV, Zoetendal EG, Hart A. The gut microbiota and host health: a new clinical frontier. Gut 2016;65:330–339.

9. Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis 2015;26:26191.

10. Ferreira CM, Vieira AT, Vinolo MAR, Oliveira F a, Curi R, Martins FDS. The central role of the gut microbiota in chronic inflammatory diseases. J Immunol Res 2014;1:1–12.

11. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci 2007;104:13780–13785.

12. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Folsch UR, Timmis KN, Schreider S. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004;53:685–693.

13. Johansson MEV, Sjövall H, Hansson GC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol 2013;10:352–361.

14. Johansson MEV, Gustafsson JK, Holmen-Larsson J, Jabbar KS, Xia L, Xu H, Ghishan FK, Carvalho FA, Gewirtz AT, Sjovall H, Hansson GC. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 2014;63:281–291.

15. Palmela C, Chevarin C, Xu Z, Torres J, Sevrin G, Hirten R, Tuohy KM, Thomas LV, Zoetendal EG, Hart A. The gut microbiota and host health: a new clinical frontier. Gut 2016;65:330–339.

16. Johansson ME. Mucus layers in inflammation. Inflamm Bowel Dis 2017;312:G34.

17. Kumar M, Kissoon-Singh V, Leon-Coria A, Moreau F, Chadee K. The probiotic mixture VSL#3 reduces colonic inflammation and improves intestinal barrier function in Muc2 mucin deficient mice. Am J Physiol Gastrointest Liver Physiol 2017;312:G34–G45.

18. Melo-Gonzalez F, Fenton TM, Forss C, Smedley C, Goenka A, MacDonald AS, Thornton DJ, Travis MA. Intestinal mucus activates human dendritic cells and IL-8 production in a glycan-specific manner. J Bio Chem 2018;293:8543–8553.

19. Geva-Zatorsky N, Sefik E, Kua L, Pasman L, Tan TG, Ortiz-Lopez A, Yanortsang TB, Yang L, Jupp R, Mathis D, Benoist C, Kasper DL. Mining the human gut microbiota for immunomodulatory organisms. Cell 2017;168:928–943.

20. Kissoon-Singh V, Moreau F, Trusevych E, Chadee K. Entamoeba histolytica exacerbates epithelial tight junction permeability and proinflammatory responses in Muc2−/− mice. Am J Pathol 2013;182:852–865.

21. Bergstrom KSB, Kissoon-Singh V, Gibson DL, Ma C, Montero M, Sham HP, Ryz N, Huang T, Velichia A, Finley BB, Chadee K, Vallance BA. Muc2 Protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. PLoS Pathog 2010;6:e1000902.

22. Van der Sluis M, De Koning BaE, De Brujin ACJM, Velichia A, Meijerink JPP, Van Goudoever JB, Buller HA, Dekker J, Van Seuningen I, Renes IB, Einerhand AWC. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006;131:117–129.

23. Reikvam DH, Erofeev A, Sandvik A, Gricic V, Jahnnsen FL, Gaustad P, McCoy KD, Macpherson AJ, Meza-Zepeda LA, Johansen F-E. Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression. PLoS One 2011;6:e17996.

24. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 2005;166:409–419.

25. Pott J, Hornef M. Innate immune signalling at the intestinal epithelium in homeostasis and disease. EMBO Rep 2012;13:684–698.

26. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S. Host-gut microbiota metabolic interactions. Science 2012;336:1262–1267.

27. Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature 2016;535:75–84.

28. Sovran B, Loonen LMP, Lu P, Lu P, Hugenholtz F, Belzer C, Stoite EH, Boekschoten MV, Van Baarlen P, Kleerebezem M, de Vos P, Dekker J, Renes IB, Wells JM. IL-22-STAT3 pathway plays a key role in the maintenance of ileal homeostasis in mice lacking secreted mucus barrier. Inflamm Bowel Dis 2015;21:531–542.

29. Natividad JM, Pinto-Sanchez M, Galipeau HJ, Jury J, Jordana M, Reinisch W, Collins SM, Bercik P, Surette MG, Emma-Vercoe E, Verdu EF. Ecotherapy rich in firmicutes decreases susceptibility to colitis in a humanized gnotobiotic mouse model. Inflamm Bowel Dis 2015;21:1883–1893.

30. Brandi K, Sun L, Neppil C, Siggs OM, Le Gall SM, Tomisato W, Li X, Du X, Maennel DN, Blobel CP, Beutler B. MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. Proc Natl Acad Sci 2010;107:19967–19972.

31. Reikvam DH, Erofeev A, Sandvik A, Gricic V, Jahnnsen FL, Gaustad P, McCoy KD, Macpherson AJ, Meza-Zepeda LA, Johansen F-E. Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression. PLoS One 2011;6:e17996.

32. Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC, Burkepile DE, Vega RL, Thurber V, Knight R, Beiko RG, Huttenhower C. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 2013;31:814–821.
33. Camilleri M, Madsen K, Spiller R, Van Meerveld BG, Verne GN. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 2012; 24:503–512.

34. Atreya R, Neurath MF. IBD pathogenesis in 2014: Molecular pathways controlling barrier function in IBD. Nat Rev Gastroenterol Hepatol 2014;12:67–68.

35. Wlodarska M, Kostic AD, Xavier RJ. An integrative view of microbiome-host interactions in inflammatory bowel diseases. Cell Host Microbe 2015;17:577–591.

36. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol 2015; 37:47–55.

37. Rankin LC, Girard-Madoux MJH, Seillet C, Milieke LA, Kerdiles Y, Fenis A, Wiedewild E, Putoczki T, Mondot S, Lantz O, Demon D, Papenfuss AT, Smyth GK, Lamkanfi M, Carotta S, Renaud J-C, Shi W, Carpentier S, Soos T, Arendt C, Ugolini S, Huntington ND, Belz GT, Vivier E. Complementarity and redundancy of IL-22-producing innate lymphoid cells. Nat Immunol 2016;17:179–186.

38. Sano T, Huang W, Hall JA, Yang Y, Chen A, Gavzy SJ, Lee J-Y, Ziel JW, Miralidi ER, Domingos AI, Bonneau R, Huntington ND, Belz GT, Vivier E. Complementarity and redundancy of IL-22-producing innate lymphoid cells. Cell 2015;163:381–393.

39. Geremia A, Arancibia-Cárcamo CV. Innate lymphoid cells in intestinal inflammation. Front Immunol 2017;8:1296.

40. Turner J, Stockinger B, Helmbry H. IL-22 mediates goblet cell hyperplasia and worm expulsion in intestinal helminth infection. PLoS Pathog 2013;9:1–7.

41. Geuken MB, Köllner T, Rupp S, McCoy KD. The interplay between the gut microbiota and the immune system. Gut Microbes 2014;5:411–418.

42. Wu GD, Bushman FD, Lewis JD. Diet, the human gut microbiota, and IBD. Anaerobe 2013;24:117–120.

43. Persson EK, Scott CL, Mowat AM, Agace WW. Dendritic cell subsets in the intestinal lamina propria: ontogeny and function. Eur J Immunol 2013;43:3098–3107.

44. Scott CL, Aumeunier AM, Mowat AM. Intestinal CD103+ dendritic cells: master regulators of tolerance? Trends Immunol 2011;32:412–419.

45. Iredell J, Brown J, Tagg K. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications. BMJ 2015;351:h6420.

46. England Public Health. Investigation of Enterobacteriaceae: mechanisms and clinical implications. BMJ 2015;351:h6420.

47. Sovran B, Lu P, Loonen L, Hugenholtz F, Belzer C, Stolte EH, Boekschoten MV, Van Baarlen P, Smidt H, Kleerebezem M, de Vos P, Renes IB, Wells JM, Dekker J. Identification of commensal species positively correlated with early stress responses to a compromised mucus barrier. Inflamm Bowel Dis 2016;22:826–840.

48. Geerlings SY, Kostopoulos I, Vos WM De, Belzer C. Akkermansia muciniphila in the human gastrointestinal tract: where, when, and how? Microorganisms 2018;6:1–26.

49. Robles Alonso V, Guarner F. Linking the gut microbiota to human health. Br J Nutr 2013;109:S21–S26.

50. Lin PW, Nasr TR, Berardinelli AJ, Kumar A, Neish AS. The probiotic Lactobacillus GG may augment intestinal host defense by regulating apoptosis and promoting cytoprotective responses in the developing murine gut. Pediatr Res 2008;64:511–516.

51. Johansson MEV, Jakobsson HE, Holmén-Larsson J, Schutte A, Ernund A, Rodrigue-Pineiro AM, Arike L, Wissing C, Svensson F, Backhed F, Hansson GC. Normalization of host intestinal mucus layers requires long-term microbial colonization. Cell Host Microbe 2015;18:582–592.

52. Joo H-S, Otto M. Molecular basis of in-vivo biofilm formation by bacterial pathogens. Chem Biol 2013;19:1503–1513.

53. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBO.net Journal 2011;17:10.

54. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods 2013;10:996–998.

55. Edgar RC, Flyvbjerg H. Error filtering, pair assembly and error correction for next-generation sequencing reads. Bioinformatics 2015;31:3476–3482.

56. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 2007;73:5261–5267.

57. Köster J, Rahmann S. Snakemake — a scalable bioinformatics workflow engine. Bioinformatics 2012;28:2520–2522.

58. R Development Core Team. R: a language and environment for statistical computing; 2011.

59. McMurdie PJ, Holmes S. Phyloseq: An R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 2013;8:e61217.

60. Oksanen AJ, Blanchet FG, Friendly M, Kindt R, Legendre P, McGlinn D, Minchin PR, O’Hara RB, Simpson GL, Solymos P, Stevens MHH, Szoecs E, Wagner H. Package ‘vegan’ 2015.

61. Shannon CE. A mathematical theory of communication 1948;27:379–423.

62. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57:289–300.

63. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014;15:1–21.

64. McMurdie PJ, Holmes S. Waste not, want not: why rarifying microbiome data is inadmissible. PLOS Comput Biol 2014;10:e1003531.

65. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttenhower CA, Kelly ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirring M, Reeder J, Sevinsky J, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010;7:335–336.

66. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set
enrichment analysis: A knowledge-based approach for interpreting genome-wide. PLoS Nat Acc Sci 2005; 102:15545–15550.

67. Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omic J Integr Biol 2012;16:284–287.

68. Whelan FJ, Verschoor CP, Steams JC, Rossi L, Luinstra K, Loeb M, Smieja M, Johnstone J, Surette MG, Bowdish DM. The loss of topography in the microbial communities of the upper respiratory tract in the elderly. Ann Am Thorac Soc 2014;11:513–521.

69. Bartram AK, Lynch MDJ, Stearns JC, Moreno-Hagelsieb G, Neufeld JD. Generation of multimillion-sequence 16S rRNA gene libraries from complex microbial communities by assembling paired-end Illumina reads. Appl Environ Microbiol 2011;77:3846–3852.

70. Johansson MEV, Hansson GC. Preservation of mucus in histological sections, immunostaining of mucins in fixed tissue, and localization of bacteria with FISH. In: Mucins: Methods and Protocols, 842; 2012:229–235.

71. Viennois E, Chen F, Larou H, Baker MT, Merlin D. Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: Lithium chloride purification, a rapid and efficient technique to purify RNA. BMC Res Notes 2013;6:360.

72. Weigmann B, Tubbe I, Seidel D, Nicolaev A, Becker C, Neurath MF. Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue. Nat Protoc 2007;2:2307–2311.

73. Giuliani a, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001;25:386–401.

74. Roxas JL, Koutsouris A, Bellmeyer A, Tesfay S, Royan S, Falzari K, Harris A, Cheng H, Rhee KJ, Hecht G. Enterohemorrhagic E. coli alters murine intestinal epithelial tight junction protein expression and barrier function in Shiga toxin independent manner. Lab Invest 2010;90:1152–1168.

Received November 8, 2019. Accepted July 7, 2020.

Correspondence
Address correspondence to: Kris Chadee, PhD, Cumming School of Medicine, Department of Microbiology, Immunology and Infectious Diseases, University of Calgary Health Sciences Centre, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada. e-mail: kchadee@ucalgary.ca; fax: (403) 270-2772.

Acknowledgments
The authors thank Pina Colarusso and Rima-Marie Wazen from the Live Cell Imaging Facility at the Snyder Institute for technical assistance.

CRediT Authorship Contributions
Aralia Leon Coria (Conceptualization: Equal; Formal analysis: Lead; Investigation: Lead; Methodology: Supporting; Validation: Supporting; Writing – original draft: Lead; Writing – review & editing: Supporting)
Manish Kumar (Conceptualization: Supporting; Formal analysis: Supporting; Investigation: Supporting; Methodology: Supporting; Validation: Supporting; Visualization: Supporting; Writing – original draft: Supporting)
Matthew Workentine (Data curation: Supporting; Formal analysis: Lead; Software: Lead; Validation: Supporting)
France Moreau (Formal analysis: Supporting; Investigation: Supporting; Project administration: Supporting; Resources: Lead; Validation: Supporting)
Michael Surette (Data curation: Lead; Formal analysis: Supporting; Methodology: Supporting; Software: Supporting; Validation: Supporting)
Kris Chadee (Conceptualization: Equal; Funding acquisition: Lead; Project administration: Lead; Supervision: Lead; Validation: Equal; Writing – review & editing: Equal)

Conflicts of interest
The authors disclose no conflicts.

Funding
Operating grants from Crohn’s and Colitis Canada and the Canadian Institute of Health Research supported this work. Aralia Leon-Coria was supported by scholarships from CONACyT and NSERC-CREATE.